INTRODUCTION
In this paper, an approach is described in which a coupled mathematical model has been developed that is capable of describing the in vitro drug kinetics of the anti-cancer agent topotecan (TPT) for single human osteosarcoma cells linked to primary biological (cell cycle) responses. The model offers the possibility of demonstrating both the dynamic and temporal interactions of active drug delivered to its DNA-associated molecular target and the downstream impact on cell growth and death. Live-cell data generated from new experimental procedures have been used and these procedures were developed to meet the demands of model comparison/validation [1] . In order to do this a series of robust quantitative laboratory assays have been designed to track and measure time-integrated events at the single cell level. Acquired data are used for parameter estimation and model simulation to further investigate the interactions of the drug with its target and possible routes for cellular evasion of drug action (i.e. drug resistance). The aim of this study was to assess the possibility of linking an existing drug kinetic model (for TPT) with a basic model for cell cycle dynamics [2] . Ultimately, a robust and validated version of such a generic model could be used to design and predict the consequences and potential failure of drug treatment regimens.
In Section 2 an outline of coupled drug kinetic -cell cycle response modelling and the underlying biochemistry for TPT is provided. The mathematical model developed is described in Section 3 and the methods for data collection and database generation are given in Section 4. The parameter estimation approach is presented in Section 5. Results from the parameter estimation using the experimental data are provided in Section 6.
BACKGROUND

Coupled Drug Kinetics/Cell Cycle Response Modelling
In general the relationships between drug kinetics and the drug's effect on the cell cycle are extremely complicated, especially when the perturbed biological system being modelled expresses discrete events within a heterogeneous cellular population. The linking of drug kinetics and cell cycle models to describe the kinetics for heterogeneous cell populations is relatively new. A recent model, developed independently by Alarcón et al. [3] considers an approach that uses the cell cycle as a descriptor of the biological response. A current drawback is the difficulty in obtaining model validation or comparison with experimental data.
Critical to the modelling of the cell cycle responses to the action of topotecan is the ability to undertake high temporal resolution monitoring of cell cycle progression enabling the tracking of a single cell in a non-invasive manner even within heterogeneous populations. The green fluorescent protein (GFP)-based probe has expression, location and destruction characteristics that shadow cyclin B1 dynamics in living cells [4] . The non-perturbing stealth reporter performance has been validated on high content to high throughput detection platforms comprising multi-well high-throughput screen (HTS) imaging, single cell kinetic-tracking and multi-parameter flow cytometry [4, 5] . Cyclin 
Introduction to TPT: Action of the drug
The anti-cancer agent considered here is TPT. It was selected on the basis of the experimental and clinical evidence for its primary cytotoxic activity against lung, breast and ovarian cancers [6] . TPT is a water-soluble derivative of camptothecin (CPT), an alkaloid isolated from the tree camptotheca acuminata, and acts as a DNA topoisomerase I, (topo I), inhibitor [7] . Topo I is a nuclear enzyme involved in DNA replication and repair. The enzyme unwinds supercoiled double stranded DNA (dsDNA) by temporarily binding to and cleaving one of the strands, forming a 'cleavable complex'. DNA cleavage and ligation reactions catalysed by the enzyme are tightly controlled and are normally barely detectable. The cleavage is coupled with religation to restore continuity to the DNA complex (Figure 2(a) ). In the presence of TPT, the cleaved DNA-topo I complex is stabilised, effectively inhibiting religation and resulting in accrual of complexes each sequestering a strand-break (Figure 2(b) ). The drug-induced single-strand breaks are reversible upon drug removal since the drug is non-covalently associated with DNA in forming the cleavable complex. Such lesions are considered non-toxic as they can be easily repaired/reversed. However, as replication proceeds double-strand breaks can be generated by the collision of a replication fork with the trapped complex -these lesions being responsible for the primary cytotoxic effects of TPT.
(Figure 2 in here)
TPT is of particular interest since the agent has intrinsic specificity for the DNA replication period in terms of the origin of drug responses and in terms of the growth and division cycle for outcomes (Figures 3 and 4) . The mammalian somatic cell cycle comprises four distinct phases. In G1, the chromosomes are unreplicated and the cell is uncommitted to division. During transition from this phase to S phase the cell commits to replication if DNA integrity is not compromised. DNA is then replicated and paired chromatids form. This is followed by the G2 phase where chromosomal material is prepared by the surveillance of its integrity (e.g. persistence of double-strand breaks sensed at a checkpoint) prior to commitment to mitosis. In M phase the nuclear membrane is lost, chromatin condenses and sister chromatids are separated with each daughter cell receiving a copy of each. Subsequently, the diploid 2n complement of chromosomes decondense in each daughter cell and the nuclear membrane is re-formed as cytokinesis is completed. The processes involved are distinct and tightly regulated both temporally and spatially [8] . For modelling purposes the cell cycle may be thought of as comprising two alternative states: G1 and S-G2-M separated by irreversible Start and Finish transitions, as defined by Tyson and Novak [2] . Start is defined as where the cell begins replication and Finish where the DNA replication is complete. Finish cannot occur if there have been any problems with DNA replication or chromosome alignment ( Figure 4 ). Since TPT is believed to be S-phase specific many cells may resist the agent's effects by failing to enter S phase (i.e. attempt to replicate DNA) during a finite exposure [9] . Blocking entry to S-phase halts the expansion of the cell population (i.e. cytostasis) and under some conditions can cause cell death (i.e. apoptosis). 
is the instantaneous concentration of bound drug. Dissociation of bound drug is assumed to be linear with rate constants dl k or dh k for TPT-L and TPT-H respectively. The set of ODEs describing the system is given by: The drug is administered as a bolus injection of active form only into the medium at time t = 0 (to give a concentration of D μM with respect to the total volume, V T ) and so the initial conditions for the model are given by:
The pH level at which the experiments were undertaken was 7.2. Estimated values for the drug kinetics model parameters are provided in [11] .
After one hour the medium is exchanged for drug-free medium (washout) and the cell tracking begins. To model washout at t = 1 h the variables relating to drug in the medium are instantaneously set to 0, that is: 
where the components in the square brackets refer to concentrations, m represents the mass of the cell, m is the maximum size to which a cell can grow, μ is the specific growth rate, k i s are rate constants and J i s are relevant Michaelis-Menten constants. In addition, when [CycB] falls below a certain threshold (taken to be 0.1 [2] ) cell division occurs so that m → m/2. It is assumed that the reaction between TPT and topo I is instantaneous, (as observed experimentally), and the level of the latter is constant. Values for the parameters are defined in Table 1 . These are characterised by those given in Tyson and Novak [2] and have been appropriately scaled with respect to time according
to the live-cell data provided from our experiments.
EXPERIMENTAL DATA COLLECTION AND DATABASE GENERATION
Generation of single-cell experimental data for cyclin B1 dynamics and incorporation At the end of the experiment the images were stacked and saved in *.stk or *.AVI format.
FluroTRAK [12] , an in-house software package written in Perl and developed by the Cardiff co-authors, was used to link and interact with commercial image analysis software, Metamorph (Molecular Devices Ltd, UK), to encode and transform the images into a parameterised database (see Figure 7a ). The implementation of the lineage databases can be found at http://biodiversity.cs.cf.ac.uk/cymart/. CyMART provides the home for a number of databases where the core concept is to develop a bioinformatics environment where analysis tools efficiently encode microscopy images into numbers and deposit the encoded data in relational databases. 
MODEL PARAMETER ESTIMATION
Using estimated drug kinetics model parameters [11] 
where sim () j yt is the model output at the j th sampling time (t j ) and obs () yj is the corresponding experimental data point. An estimate for the standard error for the output is provided by eR , in which e = 0.1 is the estimated overall accuracy of the data (an assumed overall error of 10%) and R is the range for sim () j yt [13] . This approach is also referred to as a weighted least squares method as the random error at each sampling time Confidence levels provide a statistical measure of how well the parameters are defined by the model and the data. FACSIMILE works in terms of internal parameters that are the natural logarithms of the given model parameters. Information is also returned on the estimated correlation between the estimated parameters and the standard deviation of the natural logarithm (SDLN) of each of the well-determined parameters, p 0 , which is estimated from the variance-covariance matrix of p-p 0 [13] .
RESULTS
The parameter values and estimated parameter values, with estimates for their confidences are provided in Table 1 . The plots shown in Figure 8 show three typical traces for the growth of a cell in the absence and presence of 1 and 10µM TPT. The livecell data are denoted by the grey circles and the simulated data by the solid black curve.
( Table 1 in However, these spikes correspond to morphological changes in the cell during mitosis.
As the cell grows, its shape changes and just before division the cell 'rounds up' becoming spherical in shape. The light reflected back, a measure of the fluorescence, is at its most intense at this stage resulting in a false peak in the data. The parameter estimation attempts to allow for this by capping the data at some chosen fixed level. The relationship between Cdk-Cyclin B and APC during the cell cycle. At G1, Cdk activity is low and cyclin B1 is rapidly degraded and then at Start, cyclin B1 levels are promoted. Cdk levels rapidly rise and are maintained through S, G2 and M while at Finish, APC proteins are activated and specific proteins degraded. 
CONCLUDING REMARKS
